Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 4/20 | 0.37 |
| ▸ | DPP4 | P27487 | 3/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1022056 | 1.00 | ACE (0.40) | ACECNR2DPP4DPP8DPP7 | |
| SCHEMBL28789465 | 1.00 | ACE (0.40) | ACECNR2DPP4DPP8DPP7 | |
| SCHEMBL1652402 | 0.83 | ACE (0.54) | ACEDPP4DPP8DPP7PREP | |
| SCHEMBL9409947 | 0.83 | ACE (0.54) | ACEDPP4DPP8DPP7PREP | |
| SCHEMBL19253042 | 0.83 | ACE (0.54) | ACEDPP4DPP8DPP7PREP | |
| SCHEMBL30811430 | 0.79 | CNR2 (0.38) | ACECNR2DPP4DPP8PREP | |
| SCHEMBL31472471 | 0.79 | CNR2 (0.38) | ACECNR2DPP4DPP8PREP | |
| SCHEMBL7771045 | 0.77 | TSHR (0.41) | ACECNR2DPP4DPP8DPP7 | |
| SCHEMBL1021746 | 0.77 | CNR2 (0.37) | ACECNR2PREP | |
| SCHEMBL5743175 | 0.77 | CNR2 (0.37) | ACECNR2PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4543878-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES | Astrazeneca AB (SE) | 2025-04-30 | — | — | EP | disclosed |
| EP-4543877-A1 | SOLID-STATE FORMS OF N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)- 6-MORPHOLINOQUINOLINE-4-CARBOXAMIDE | Astrazeneca AB (SE) | 2025-04-30 | — | — | EP | disclosed |
| WO-2023247487-A1 | SOLID-STATE FORMS OF N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)- 6-MORPHOLINOQUINOLINE-4-CARBOXAMIDE | ASTRAZENECA AB (SE) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023247489-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023248871-A1 | HETEROARYL COMPOUND AND PEST CONTROL AGENT | 日本曹達株式会社 | 2023-12-28 | — | — | WO | disclosed |
| CN-101868457-B | (3-hydroxy-4-amino-but-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for use in therapy | COMENTIS INC | 2013-02-13 | — | — | CN | disclosed |
| CN-101868457-A | (3-hydroxy-4-amino-but-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for use in therapy | COMENTIS INC | 2010-10-20 | — | — | CN | disclosed |
| US-20060229286-A1 | Compound inhibiting dipeptidyl peptidase IV | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229286-A1 | Compound inhibiting dipeptidyl peptidase IV | DPP4, DPP3, DPP7 | ACE 123/4885CNR2 516/4885DPP4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.